How often is Denosumab (Prolia) administered?

• A. Every month
• B. Every 3 months
• C. Every 6 months
• D. Every year

Answer: (C)

Denosumab, marketed under the brand name Prolia, is administered subcutaneously and is indicated for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture, as well as for the treatment of bone loss in cancer patients receiving hormone ablation therapy. The correct administration frequency is every 6 months.

This biannual dosing schedule is designed to maintain effective serum levels of the medication, which helps in reducing bone resorption and promoting bone density over time. The medication's pharmacokinetics and dynamics are such that it can provide sustained effects without requiring more frequent dosing, which enhances patient compliance and ensures consistent therapeutic results.

The other options represent inappropriate dosing intervals based on the established protocols for Denosumab, thus emphasizing the importance of adhering to the recommended 6-month schedule for optimal management of osteoporosis and related conditions.